- “The law and regulation for surrogate endpoints with attention to history and changing interpretations” — Holly Fernandez Lynch, JD, MBe (University of Pennsylvania)
- “The case for beta-amyloid as measured by PET” — Dennis Selkoe, MD (Harvard University)
- “The case against beta-amyloid as measured by PET” — Chris van Dyck, MD (Yale University)
Are we there yet with PET? – Internal Ethics Committee Webinar Invitation
Jason Karlawish, MD, and Joshua Grill, PhD, co-chairs of the Internal Ethics Committee of the Alzheimer’s Clinical Trial Consortium (ACTC, NIA U24 AG057437), together with the committee members invite you to “Are we there yet with PET?” a virtual debate over amyloid PET as a surrogate endpoint for clinically meaningful outcomes. The goal of this debate is to inform the Alzheimer’s field about regulatory approaches that have been applied in the reviews of aducanumab, lecanemab and donanemab. This discussion will be recorded. 4 p.m. February 23, 2023 | Click here to register Topics:
